Low Incidence of Malignancy after Heart Transplantation in Taiwan

Y. J. Wang, N. H. Chi, N. K. Chou, S. C. Huang, C. H. Wang, I. H. Wu, H. Y. Yu, Y. S. Chen, C. I. Tsao, C. T. Shun, J. T. Tsai, S. S. Wang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Malignancy is the leading cause of death in Taiwan. The risk of malignancy is higher in heart transplant recipients than in the general population. We reviewed the malignancy incidence among the patients who underwent heart transplantation (HT) at the National Taiwan University Hospital (NTUH) during the past 28 years. We found that the incidence of malignancy is low in Taiwan and that the pattern of malignancy is different from that in the Western population. Methods From July 1987 to March 2015, 518 patients underwent HT at NTUH. Forty-four patients who died within 1 month after transplantation were excluded from this study. Thus, a total of 476 patients were enrolled in this study. There were 393 male and 83 female patients, with a mean age of 45 years at transplantation. The major indications for HT were dilated cardiomyopathy (52%) and ischemic cardiomyopathy (33%). After HT, all patients received triple immunosuppressive therapy, including a calcineurin inhibitor (cyclosporine or tacrolimus), cell-cycle inhibitor (azathioprine, mycophenolate mofetil, or everolimus), and steroid. After 1995, induction with rabbit anti-human thymocyte globulin was routinely performed. Survival was estimated by means of the Kaplan-Meier method. Results Twenty-seven patients without pre-transplantation malignancy developed malignancies after HT. The median survival time (MST) of these 27 HT patients was 76.8 months. After malignancy was diagnosed, the overall MST was 20.7 months. The 3- and 5-year overall survival rates were 44% and 27%, respectively. Twenty-one patients (77.8%) died, 10 of them because of cancer. The most common malignancy was non-Hodgkin lymphoma (n = 6), followed by skin cancer (including 2 keratoacanthomas, 2 squamous cell carcinomas, and 1 basal cell carcinoma; n = 5) and lung squamous cell carcinoma (n = 3). The univariate analysis identified cancer stage (P =.044) and comorbidity (P =.002) as factors associated with poor malignancy survival. In the multivariate analysis, comorbidity was an independent prognostic factor for greater risk of death because of post-transplantation malignancy (P =.002). Conclusions In Taiwan, the risk of malignancy after HT is low (5.7%), as is the incidence of skin cancer. The most common malignancy was non-Hodgkin lymphoma, followed by skin cancer and lung cancer. Comorbidity was an independent factor for overall survival in cancer patients who previously underwent HT.

Original languageEnglish
Pages (from-to)974-977
Number of pages4
JournalTransplantation Proceedings
Volume48
Issue number3
DOIs
Publication statusPublished - Apr 1 2016

Fingerprint

Heart Transplantation
Taiwan
Incidence
Neoplasms
Skin Neoplasms
Transplantation
Survival
Comorbidity
Non-Hodgkin's Lymphoma
Squamous Cell Carcinoma
Lung Neoplasms
Keratoacanthoma
Mycophenolic Acid
Antilymphocyte Serum
Basal Cell Carcinoma
Azathioprine
Dilated Cardiomyopathy
Tacrolimus
Immunosuppressive Agents
Cardiomyopathies

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Wang, Y. J., Chi, N. H., Chou, N. K., Huang, S. C., Wang, C. H., Wu, I. H., ... Wang, S. S. (2016). Low Incidence of Malignancy after Heart Transplantation in Taiwan. Transplantation Proceedings, 48(3), 974-977. https://doi.org/10.1016/j.transproceed.2015.12.079

Low Incidence of Malignancy after Heart Transplantation in Taiwan. / Wang, Y. J.; Chi, N. H.; Chou, N. K.; Huang, S. C.; Wang, C. H.; Wu, I. H.; Yu, H. Y.; Chen, Y. S.; Tsao, C. I.; Shun, C. T.; Tsai, J. T.; Wang, S. S.

In: Transplantation Proceedings, Vol. 48, No. 3, 01.04.2016, p. 974-977.

Research output: Contribution to journalArticle

Wang, YJ, Chi, NH, Chou, NK, Huang, SC, Wang, CH, Wu, IH, Yu, HY, Chen, YS, Tsao, CI, Shun, CT, Tsai, JT & Wang, SS 2016, 'Low Incidence of Malignancy after Heart Transplantation in Taiwan', Transplantation Proceedings, vol. 48, no. 3, pp. 974-977. https://doi.org/10.1016/j.transproceed.2015.12.079
Wang, Y. J. ; Chi, N. H. ; Chou, N. K. ; Huang, S. C. ; Wang, C. H. ; Wu, I. H. ; Yu, H. Y. ; Chen, Y. S. ; Tsao, C. I. ; Shun, C. T. ; Tsai, J. T. ; Wang, S. S. / Low Incidence of Malignancy after Heart Transplantation in Taiwan. In: Transplantation Proceedings. 2016 ; Vol. 48, No. 3. pp. 974-977.
@article{ea98e3b05d71485badd43fe72b441b7f,
title = "Low Incidence of Malignancy after Heart Transplantation in Taiwan",
abstract = "Background Malignancy is the leading cause of death in Taiwan. The risk of malignancy is higher in heart transplant recipients than in the general population. We reviewed the malignancy incidence among the patients who underwent heart transplantation (HT) at the National Taiwan University Hospital (NTUH) during the past 28 years. We found that the incidence of malignancy is low in Taiwan and that the pattern of malignancy is different from that in the Western population. Methods From July 1987 to March 2015, 518 patients underwent HT at NTUH. Forty-four patients who died within 1 month after transplantation were excluded from this study. Thus, a total of 476 patients were enrolled in this study. There were 393 male and 83 female patients, with a mean age of 45 years at transplantation. The major indications for HT were dilated cardiomyopathy (52{\%}) and ischemic cardiomyopathy (33{\%}). After HT, all patients received triple immunosuppressive therapy, including a calcineurin inhibitor (cyclosporine or tacrolimus), cell-cycle inhibitor (azathioprine, mycophenolate mofetil, or everolimus), and steroid. After 1995, induction with rabbit anti-human thymocyte globulin was routinely performed. Survival was estimated by means of the Kaplan-Meier method. Results Twenty-seven patients without pre-transplantation malignancy developed malignancies after HT. The median survival time (MST) of these 27 HT patients was 76.8 months. After malignancy was diagnosed, the overall MST was 20.7 months. The 3- and 5-year overall survival rates were 44{\%} and 27{\%}, respectively. Twenty-one patients (77.8{\%}) died, 10 of them because of cancer. The most common malignancy was non-Hodgkin lymphoma (n = 6), followed by skin cancer (including 2 keratoacanthomas, 2 squamous cell carcinomas, and 1 basal cell carcinoma; n = 5) and lung squamous cell carcinoma (n = 3). The univariate analysis identified cancer stage (P =.044) and comorbidity (P =.002) as factors associated with poor malignancy survival. In the multivariate analysis, comorbidity was an independent prognostic factor for greater risk of death because of post-transplantation malignancy (P =.002). Conclusions In Taiwan, the risk of malignancy after HT is low (5.7{\%}), as is the incidence of skin cancer. The most common malignancy was non-Hodgkin lymphoma, followed by skin cancer and lung cancer. Comorbidity was an independent factor for overall survival in cancer patients who previously underwent HT.",
author = "Wang, {Y. J.} and Chi, {N. H.} and Chou, {N. K.} and Huang, {S. C.} and Wang, {C. H.} and Wu, {I. H.} and Yu, {H. Y.} and Chen, {Y. S.} and Tsao, {C. I.} and Shun, {C. T.} and Tsai, {J. T.} and Wang, {S. S.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.transproceed.2015.12.079",
language = "English",
volume = "48",
pages = "974--977",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Low Incidence of Malignancy after Heart Transplantation in Taiwan

AU - Wang, Y. J.

AU - Chi, N. H.

AU - Chou, N. K.

AU - Huang, S. C.

AU - Wang, C. H.

AU - Wu, I. H.

AU - Yu, H. Y.

AU - Chen, Y. S.

AU - Tsao, C. I.

AU - Shun, C. T.

AU - Tsai, J. T.

AU - Wang, S. S.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Background Malignancy is the leading cause of death in Taiwan. The risk of malignancy is higher in heart transplant recipients than in the general population. We reviewed the malignancy incidence among the patients who underwent heart transplantation (HT) at the National Taiwan University Hospital (NTUH) during the past 28 years. We found that the incidence of malignancy is low in Taiwan and that the pattern of malignancy is different from that in the Western population. Methods From July 1987 to March 2015, 518 patients underwent HT at NTUH. Forty-four patients who died within 1 month after transplantation were excluded from this study. Thus, a total of 476 patients were enrolled in this study. There were 393 male and 83 female patients, with a mean age of 45 years at transplantation. The major indications for HT were dilated cardiomyopathy (52%) and ischemic cardiomyopathy (33%). After HT, all patients received triple immunosuppressive therapy, including a calcineurin inhibitor (cyclosporine or tacrolimus), cell-cycle inhibitor (azathioprine, mycophenolate mofetil, or everolimus), and steroid. After 1995, induction with rabbit anti-human thymocyte globulin was routinely performed. Survival was estimated by means of the Kaplan-Meier method. Results Twenty-seven patients without pre-transplantation malignancy developed malignancies after HT. The median survival time (MST) of these 27 HT patients was 76.8 months. After malignancy was diagnosed, the overall MST was 20.7 months. The 3- and 5-year overall survival rates were 44% and 27%, respectively. Twenty-one patients (77.8%) died, 10 of them because of cancer. The most common malignancy was non-Hodgkin lymphoma (n = 6), followed by skin cancer (including 2 keratoacanthomas, 2 squamous cell carcinomas, and 1 basal cell carcinoma; n = 5) and lung squamous cell carcinoma (n = 3). The univariate analysis identified cancer stage (P =.044) and comorbidity (P =.002) as factors associated with poor malignancy survival. In the multivariate analysis, comorbidity was an independent prognostic factor for greater risk of death because of post-transplantation malignancy (P =.002). Conclusions In Taiwan, the risk of malignancy after HT is low (5.7%), as is the incidence of skin cancer. The most common malignancy was non-Hodgkin lymphoma, followed by skin cancer and lung cancer. Comorbidity was an independent factor for overall survival in cancer patients who previously underwent HT.

AB - Background Malignancy is the leading cause of death in Taiwan. The risk of malignancy is higher in heart transplant recipients than in the general population. We reviewed the malignancy incidence among the patients who underwent heart transplantation (HT) at the National Taiwan University Hospital (NTUH) during the past 28 years. We found that the incidence of malignancy is low in Taiwan and that the pattern of malignancy is different from that in the Western population. Methods From July 1987 to March 2015, 518 patients underwent HT at NTUH. Forty-four patients who died within 1 month after transplantation were excluded from this study. Thus, a total of 476 patients were enrolled in this study. There were 393 male and 83 female patients, with a mean age of 45 years at transplantation. The major indications for HT were dilated cardiomyopathy (52%) and ischemic cardiomyopathy (33%). After HT, all patients received triple immunosuppressive therapy, including a calcineurin inhibitor (cyclosporine or tacrolimus), cell-cycle inhibitor (azathioprine, mycophenolate mofetil, or everolimus), and steroid. After 1995, induction with rabbit anti-human thymocyte globulin was routinely performed. Survival was estimated by means of the Kaplan-Meier method. Results Twenty-seven patients without pre-transplantation malignancy developed malignancies after HT. The median survival time (MST) of these 27 HT patients was 76.8 months. After malignancy was diagnosed, the overall MST was 20.7 months. The 3- and 5-year overall survival rates were 44% and 27%, respectively. Twenty-one patients (77.8%) died, 10 of them because of cancer. The most common malignancy was non-Hodgkin lymphoma (n = 6), followed by skin cancer (including 2 keratoacanthomas, 2 squamous cell carcinomas, and 1 basal cell carcinoma; n = 5) and lung squamous cell carcinoma (n = 3). The univariate analysis identified cancer stage (P =.044) and comorbidity (P =.002) as factors associated with poor malignancy survival. In the multivariate analysis, comorbidity was an independent prognostic factor for greater risk of death because of post-transplantation malignancy (P =.002). Conclusions In Taiwan, the risk of malignancy after HT is low (5.7%), as is the incidence of skin cancer. The most common malignancy was non-Hodgkin lymphoma, followed by skin cancer and lung cancer. Comorbidity was an independent factor for overall survival in cancer patients who previously underwent HT.

UR - http://www.scopus.com/inward/record.url?scp=84970024692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84970024692&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2015.12.079

DO - 10.1016/j.transproceed.2015.12.079

M3 - Article

C2 - 27234782

AN - SCOPUS:84970024692

VL - 48

SP - 974

EP - 977

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 3

ER -